Clay co-founded PhaseBio Pharmaceuticals in 2002 and has served as a member of the company’s board of directors since that time. He has served as Chairman of PhaseBio since November 2014. Since 1995, Clay has co-founded eight life sciences companies, including PhaseBio. He also co-founded Hatteras Venture Partners in 2000, where he has been instrumental in building the firm from its origins with a $3 million seed fund to a venture capital partnership that manages over $350 million across five funds. Clay was co-founder, CEO and Chairman of Synthematix, Inc., a chemistry informatics company acquired in April 2005 by Symyx Technologies. He was the co-founder and Head of Corporate Development for Novalon Pharmaceutical Corporation, where he led financing efforts and was Head of Business Development from inception until Novalon’s sale to Karo Bio for $106.7 million in May 2000. Prior to Novalon, Clay was the co-founder and President of Xanthon, Inc., a bioinformatics company with electro-chemical detection technology for direct analysis of DNA, RNA and proteins. Clay currently serves on the boards of Clearside Biomedical and Vigil Neuroscience. He received a BA in mathematics and art history from the University of North Carolina at Chapel Hill and a Masters of Public Policy from Harvard University.